Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein–Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients

Abstract

Epstein-Barr virus (EBV) is associated with several malignancies including nasopharyngeal carcinoma, a high incidence tumor in Chinese populations, in which tumor cells express the two EBV antigens EB nuclear antigen 1 (EBNA1) and latent membrane protein 2 (LMP2). Here, we report the phase I trial of a recombinant vaccinia virus, MVA-EL, which encodes an EBNA1/LMP2 fusion protein designed to boost T-cell immunity to these antigens. The vaccine was delivered to Hong Kong patients with nasopharyngeal carcinoma to determine a safe and immunogenic dose. The patients, all in remission more than 12 weeks after primary therapy, received three intradermal MVA-EL vaccinations at three weekly intervals, using five escalating dose levels between 5 Â 10 7 and 5 Â 10 8 plaque-forming unit (pfu). Blood samples were taken during prescreening, immediately before vaccination, one week afterward and at intervals up to one year later. Immunogenicity was tested by IFN-g ELIspot assays using complete EBNA1 and LMP2 15-mer peptide mixes and known epitope peptides relevant to patient MHC type. Eighteen patients were treated, three per dose level one to four and six at the highest dose, without dose-limiting toxicity. T-cell responses to one or both vaccine antigens were increased in 15 of 18 patients and, in many cases, were mapped to known CD4 and CD8 epitopes in EBNA1 and/or LMP2. The range of these responses suggested a direct relationship with vaccine dose, with all six patients at the highest dose level giving strong EBNA1/LMP2 responses. We concluded that MVA-EL is both safe and immunogenic, allowing the highest dose to be forwarded to phase II studies examining clinical benefit. Cancer Res; 73(6); 1676-88. Ó2012 AACR.

Frequency of Epstein-Barr virus DNA sequences in human gliomas

“…29 In that study, it was concluded that the vaccine is both safe and immunogenic, thus allowing the highest dose to be moved forward to phase II studies. From our data, it is possible that in the future, in the same way as seen among those nasopharyngeal carcinoma patients, tests using an EBV vaccine may be found to benefit glioma patients.…”

Mortality in Schizophrenia: Clinical and Serological Predictors

“…There are a number of available and experimental medications that can inhibit the replication of EBV, 35 and experimental vaccines directed at EBV have been developed and evaluated in phase 1 trials. 36 The better understanding of the role of EBV in mortality might 43/F I21.9 Acute myocardial infarction (diseases of circulatory system, ischemic heart disease) 3.…”

Therapeutic cancer vaccines

“…EBV-induced nasopharyngeal carcinoma (NPC) or other EBVinduced malignancies (65)(66)(67) showed that the vaccine was well tolerated and elicited antigen-specific T cell responses. An EBV vaccine could potentially prevent the development of EBVinduced malignancies, even if it does not prevent transmission of the virus (68).…”